Sugi Predict

Sugi Predict / Compounds / SCHEMBL167199

SCHEMBL167199

SCHEMBL167199

CCOC(=O)C(C)(C)Cc1c(SC(C)(C)C)c2cc(O)ccc2n1Cc1ccc(Cl)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGES2 Q9H7Z7 2/20 0.66
▸ ALOX5AP P20292 17/20 0.61
▸ ALOX5 P09917 10/20 0.61
▸ CYP3A4 P08684 4/20 0.61
▸ CYP2C9 P11712 4/20 0.61
▸ MEN1 O00255 3/20 0.61
▸ USP2 O75604 3/20 0.61
▸ TP53 P04637 3/20 0.61
▸ CYP1A2 P05177 3/20 0.61
▸ POLB P06746 3/20 0.61
▸ MAPT P10636 3/20 0.61
▸ HPGD P15428 3/20 0.61
▸ ALOX15 P16050 3/20 0.61
▸ MAPK1 P28482 3/20 0.61
▸ RECQL P46063 3/20 0.61
▸ BLM P54132 3/20 0.61
▸ KMT2A Q03164 3/20 0.61
▸ NPSR1 Q6W5P4 3/20 0.61
▸ HSD17B10 Q99714 3/20 0.61
▸ KDM4E B2RXH2 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12014953 0.94 PTGES2 (0.57) PTGES2ALOX5APALOX5CYP3A4CYP2C9
SCHEMBL10264786 0.92 PTGES2 (0.56) PTGES2ALOX5APALOX5CYP3A4CYP2C9
SCHEMBL176187 0.92 PTGES2 (0.56) PTGES2ALOX5APALOX5CYP3A4CYP2C9
SCHEMBL25968196 0.92 PTGES2 (0.67) PTGES2ALOX5APALOX5CYP3A4CYP2C9
SCHEMBL9044180 0.91 PTGES2 (0.80) PTGES2ALOX5APALOX5CYP3A4CYP2C9
SCHEMBL9047849 0.89 PTGES2 (0.62) PTGES2ALOX5APALOX5CYP3A4CYP2C9
SCHEMBL23270778 0.89 PTGES2 (0.83) PTGES2ALOX5APALOX5CYP3A4CYP2C9
SCHEMBL169604 0.89 PTGES2 (0.67) PTGES2ALOX5APALOX5CYP3A4CYP2C9
SCHEMBL30181340 0.89 PTGES2 (0.83) PTGES2ALOX5APALOX5CYP3A4CYP2C9
SCHEMBL30181651 0.89 PTGES2 (0.67) PTGES2ALOX5APALOX5CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200147064-A1 Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor AUTOIMMUNE PHARMA LLC (US) 2020-05-14 — — US disclosed
WO-2018152405-A1 REDUCTION OF PRO-INFLAMMATORY HDL USING A LEUKOTRIENE INHIBITOR AUTOIMMUNE PHARMA LLC (US) 2018-08-23 — — WO disclosed
US-8841295-B2 5-lipoxygenase-activating protein (FLAP) inhibitors PANMIRA PHARMACEUTICALS, LLC (US) 2014-09-23 — — US disclosed
US-8710081-B2 5-lipoxygenase-activating protein (FLAP) inhibitors PANMIRA PHARMACEUTICALS, LLC (US) 2014-04-29 — — US disclosed
US-20140018394-A1 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AUTOIMMUNE PHARMA LLC 2014-01-16 — — US disclosed
US-8546431-B2 5-lipoxygenase-activating protein (FLAP) inhibitors PANMIRA PHARMACEUTICALS, LLC (US) 2013-10-01 — — US disclosed
US-20130102636-A1 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors Panmira Pharmaceuticals, Inc. (US) 2013-04-25 — — US disclosed
US-8399666-B2 5-lipoxygenase-activating protein (FLAP) inhibitors PANMIRA PHARMACEUTICALS, LLC (US) 2013-03-19 — — US disclosed
EP-1943219-B8 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS PANMIRA PHARMACEUTICALS LLC (US) 2012-03-07 — — EP disclosed
EP-2404904-A1 5-lipoxygenase-activating protein (FLAP) inhibitors Amira Pharmaceuticals, Inc. (US) 2012-01-11 — — EP disclosed
WO-2008067566-A1 COMPOSITIONS AND TREATMENTS COMPRISING 5-LIPOXYGENASE-ACTIVATING PROTEIN INHIBITORS AND NITRIC OXIDE MODULATORS AMIRA PHARMACEUTICALS, INC. (US) 2008-06-05 — — WO disclosed
US-20070244128-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-10-18 — — US disclosed
US-20070219206-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-09-20 — — US disclosed
WO-2007056021-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-18 — — WO disclosed
WO-2007056228-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (GB) 2007-05-18 — — WO disclosed
WO-2007056220-A2 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-18 — — WO disclosed
US-20070105866-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS AMIRA PHARMACEUTICALS, INC. (US) 2007-05-10 — — US disclosed
US-5420282-A Inhibitors of leukotriene biosynthesis ABBOTT LABORATORIES (US) 1995-05-30 — — US disclosed
US-5399699-A Lipoxygenase inihibitors, antiallergens, antiinflammatory agents ABBOTT LABORATORIES (US) 1995-03-21 — — US disclosed
US-5288743-A Lipoxygenase inhibitors ABBOTT LABORATORIES (US) 1994-02-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105866-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 PTGES2 29/4885ALOX5AP 4/4885ALOX5 1/4885
US-20070244128-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 PTGES2 29/4885ALOX5AP 4/4885ALOX5 1/4885
US-20200147064-A1 Reduction of Pro-Inflammatory HDL Using a Leukotriene Inhibitor LTB4R, LTC4S, LTB4R2 PTGES2 21/4885ALOX5AP 35/4885ALOX5 7/4885
US-20070219206-A1 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, ALOX15B, ALOX15 PTGES2 29/4885ALOX5AP 4/4885ALOX5 1/4885
US-20140018394-A1 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS ALOX5, LTA4H, ALOX5AP PTGES2 44/4885ALOX5AP 3/4885ALOX5 1/4885
US-20130102636-A1 5-Lipoxygenase-Activating Protein (FLAP) Inhibitors ALOX5, ALOX15B, ALOX15 PTGES2 34/4885ALOX5AP 4/4885ALOX5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.